Artificial intelligence (AI) and natural language processing (NLP) are increasingly used to extract, integrate, and interpret biomedical knowledge relevant to cancer genomics, yet their translation in...
OpenMTB‑Audit is an open‑source benchmark that tests large language models on 500 synthetic non‑small cell lung cancer cases, covering five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. The study found that all eight tested LLMs over‑refused Partially Supported recommendations, collapsing labels to achieve high safety scores. A deterministic seven‑module framework, MTB‑AuditAgent, was introduced to reduce over‑refusal to 6.7% and reach 91.2% accuracy, while an oncologist annotation study highlighted disagreement around the boundary between information sufficiency and treatment optimization.
By Negin Ashrafi, Jia Luo, Stacey M. Frumm, Roxana Daneshjou
The article presents a new semantic model for representing scientific evidence, specifically tailored to genetics, that extends existing standards by adding fine‑grained, domain‑specific structure. It aligns with FHIR Evidence and SEPIO, incorporates a compact vocabulary validated by SHACL, and was tested in a human‑AI annotation pilot on six genetics papers, producing 28 evidence items and 95 source‑anchored assertions. The authors argue that this model advances trustworthy, AI‑ready infrastructure for variant interpretation by providing a reference data model and validation schema for genetic evidence.
By Michael Bouzinier, Dmitry Etin
arXiv:2506. 10912v4 Announce Type: replace Abstract: Toxicity remains a leading cause of early-stage drug development failure.
By Fei Lin, Ziyang Gong, Cong Wang, Tengchao Zhang, Yonglin Tian, Yining Jiang, Ji Dai, Chao Guo, Xiaotong Yu, Xue Yang, Gen Luo, Fei-Yue Wang
arXiv:2608.28974v1 Announce Type: new
Abstract: Clinically relevant oncology information is distributed across heterogeneous, longitudinal documentation, creating substantial abstraction burden and r...
By Daniel Kang, Michelle Hu, Soorya Ram Shimgekar, Shayan Vassef, Yufan Wang, Anit Kumar Sahu, Munmun De Choudhury, Vedant Das Swain, Christian Poellabauer, Li Yan Khor, Koustuv Saha, Robert Wojciechowski, Elliot Kidd, Piyum Zonooz, Navin Kumar
Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological asses...
arXiv:2608.22085v1 Announce Type: new
Abstract: Synthetic clinical data generation with large language models addresses the scarcity that limits cancer staging research, but oncology hallucinations a...
By Laxmigayathri Challa, Yuhan Zhou, Ana Cleveland, Haihua Chen
LUCAID is an agentic multimodal AI system designed for precision lung cancer pathology, integrating nine modules that cover the entire routine workflow—from quality control and tumor detection to histological subtyping, microenvironment profiling, cellularity quantification, and biomarker scoring (PD‑L1, MET, TROP‑2). The system generates automated structured reports and allows interactive querying of module outputs. In prospective clinical validation, LUCAID achieved 93.0% concordance with an expert‑panel reference standard for clinically actionable decisions, outperforming five experienced thoracic pathologists who ranged from 68.3% to 81.1% concordance.
By Marie-Lisa Eich, Kai Standvoss, Timo Milbich, Alexander M\"ollers, Miriam H\"agele, Philipp Anders, Lars Tharun, Hanna Kontradiuk, Sebastian Kons, Nader Aldoj, Recepcan Adig\"uzel, Adam Narai, Lukas H\"onig, Jonathan Striebel, Binru Yang, Mihnea P. Dragomir, Marvin Sextro, Philipp Keyl, Philipp Jurmeister, Rosemarie Krupar, Evelyn Ramberger, James Wells, Julika Ribbat-Idel, Andreas Kunft, Hussam Shuaib, Christian Groh\'e, Reinhard B\"uttner, David Horst, Klaus-Robert M\"uller, Lukas Ruff, Maximilian Alber, Frederick Klauschen, Simon Schallenberg
arXiv:2512. 03296v2 Announce Type: replace-cross Abstract: Cancer treatment outcomes are influenced not only by clinical and demographic factors but also by the collaboration of healthcare teams.
By Hsiao-Ying Lu, Kwan-Liu Ma
arXiv:2510. 17532v2 Announce Type: replace-cross Abstract: Predicting cancer treatment outcomes requires models that are both accurate and interpretable, particularly in the presence of heterogeneous clinical data.
By Raghu Vamshi Hemadri, Geetha Krishna Guruju, Kristi Topollai, Anna Ewa Choromanska
arXiv:2609.01202v1 Announce Type: cross
Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...
By Yin Fang, Qiao Jin, Shubo Tian, Lauren He, Maya Geer, Noor Naffakh, Ryan Huu-Tuan Nguyen, Zifeng Wang, Jimeng Sun, Charalampos S. Floudas, James L. Gulley, Kamilia Moalem, Catarina Martins Maia, Amanda Nottke, Juan W. Valle, Melinda Bachini, Lourdes Rocha-Nussbaum, Kari Ramage, Nikita Curry, Megan Barnes, Mandy Mansaray, Darlene Gabeau, Craig E. Grossman, Heath Skinner, Michael Burczynski, NIH-TrialBench Consortium, Zhiyong Lu
arXiv:2603. 22327v2 Announce Type: replace-cross Abstract: Systematic literature reviews (SLRs) are a demanding and high-stakes form of scientific knowledge synthesis that remains underspecified as an evaluation setting for large language models (LLMs).
By Shreyansh Padarha, Ryan Othniel Kearns, Tristan Naidoo, Lingyi Yang, {\L}ukasz Borchmann, Piotr B{\L}aszczyk, Christian Morgenstern, Ruth McCabe, Sangeeta Bhatia, Philip H. Torr, Jakob Foerster, Scott A. Hale, Thomas Rawson, Anne Cori, Elizaveta Semenova, Adam Mahdi